biostudies-literatureUnknown12Nie K<h4>Objective</h4>To study the efficacy and toxicity of irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma.<h4>Patients and methods</h4>Previously untreated patients with cytologically or histologically confirmed metastatic pancreatic adenocarcinoma underwent a treatment regimen consisting of an intravenous infusion of irinotecan 165 mg/m² and oxaliplatin 85 mg/m² on day 1, and oral S-1 40 mg/m² twice daily on days 1-14, repeating the regimen every 21 days until one of the following occurred: disease progression, intolerable toxicity, or patient death. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), response rate, toxicity, and quality of life. Therapeutic advances in medical oncology1758835920970843https://www.ebi.ac.uk/biostudies/studies/S-EPMC7675906biostudies-literatureIrinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study.PMC7675906Li HYou YZhang ZGuo XNie KZhang LJi YZhang CfalseIrinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study.<h4>Objective</h4>To study the efficacy and toxicity of irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma.<h4>Patients and methods</h4>Previously untreated patients with cytologically or histologically confirmed metastatic pancreatic adenocarcinoma underwent a treatment regimen consisting of an intravenous infusion of irinotecan 165 mg/m² and oxaliplatin 85 mg/m² on day 1, and oral S-1 40 mg/m² twice daily on days 1-14, repeating the regimen every 21 days until one of the following occurred: disease progression, intolerable toxicity, or patient death. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), response rate, toxicity, and quality of life. 2020-01-01T00:00:00Z20202025-04-04T10:55:33.78Z2021-02-21T04:09:14ZS-EPMC76759063324039910.1177/1758835920970843